YaleNewHaven**Health** Smilow Cancer Hospital

Yale CANCER CENTER A Comprehensive Cancer Center Designated by the National Cancer Institute

Distinguished Lecture Series

Tuesday, December 10, 12:00pm

Brady Auditorium | <u>Zoom</u> Access Join us in person for lunch

PERSPECTIVES ON ANTI-TUMOR IMMUNITY: LEARNING FROM THE TUMOR MICROENVIRONMENT

Pamela Ohashi, PhD

Director, Tumor Immunotherapy Program, Princess Margaret Cancer Centre

Objectives:

- 1. How an anti-tumor response triggered in animal models including the specificity of the T cell response
- 2. The role of gamma delta T cells in response to PD-1 blockade
- 3. The role of innate lymphoid cells in regulating T cell immunity in ovarian cancer



Dr. Ohashi received her PhD from the University of Toronto with Dr. Tak Mak, and did her postdoctoral training at the University of Zurich with the Nobel Laureate Dr. Rolf Zinkernagel and Dr. Hans Hengartner.

She has established a research program at the Princess Margaret Cancer Centre in Toronto with a focus on CD8+ T cells, and mechanisms that modulate T cell function, particularly in the context of different tumor microenvironments. These insights are relevant for understanding how to manipulate the immune system to improve immunotherapy.

Since 2005, she has established and grown the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre, which includes a cutting-edge Immune Profiling team as well as a Cell Manufacturing team that has launched investigator-initiated clinical trials using tumor infiltrating lymphocytes, TCR transduced T cells, and CAR T cell therapy.



There is No Corporate Support for These Activities. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Designation Statement: The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity. Target Audience: YCC members, Smilow faculty, YSM, Nursing, Public Health Students. Faculty Disclosures: Winer- nothing to disclose. Ohashi - Providence Therapeutics; Rondo Therapeutics; Tikva Allocell. Financial support for serving on an Independent Data Review Committee for Cogent Biosciences.It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. Mitigation of Financial Relationships Statement: Yale CME adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

